-
CX-5461 Triggers Mitotic Catastrophe in Cervical Cancer
2026-08-28
A June 2026 study identifies a distinctive mechanism by which the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cells: DNA damage is coupled to abnormal mitotic entry, producing mitotic catastrophe, cell death, or senescence. The work also shows that CX-5461 increases cisplatin sensitivity, providing a rationale for combination strategies in treatment-resistant disease.
-
BET Inhibition in HPV-16-Associated HNSCC
2026-08-28
A bioRxiv preprint examines how BET protein inhibition alters viral and host transcription in HPV-16-associated head and neck squamous cell carcinoma. Its central finding is that BET blockade suppresses E6 and E7 but produces heterogeneous responses in p53, Rb, and viral transcription, supporting a more stratified approach to therapeutic interpretation.
-
Anti-HMGB1 Rabbit Monoclonal Antibody Guide
2026-08-27
This guide explains how to use the Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, for HMGB1 detection in Western blot, immunohistochemistry, and flow cytometry workflows. It is intended for research use with human, mouse, and rat samples, not for diagnosis, therapy, or clinical decision-making; no directly matched paper evidence was available for this specific SKU.
-
Acetylspiramycin (Spiramycin B) in Cell Assays
2026-08-27
A scenario-based guide to using Acetylspiramycin (Spiramycin B), SKU BA1075, in antimicrobial, host–pathogen, and cell viability workflows. It covers solvent compatibility, controls, assay interpretation, resistance benchmarking, and practical product-selection criteria.
-
Entecavir (BMS200475) HBV Research Workflows
2026-08-26
Entecavir (BMS200475) supports precise HBV replication studies across wild-type and lamivudine-resistant models. This workflow-focused guide covers dose-response design, DNA-polymerase readouts, formulation control, and troubleshooting for reproducible chronic hepatitis B virus replication inhibition research.
-
CB-5083: Linking p97 Inhibition to DNA Repair
2026-08-26
Explore how the p97 inhibitor CB-5083 can be used to dissect protein homeostasis disruption alongside cGAS-regulated homologous recombination. This assay-focused perspective connects mechanistic findings from naked mole-rat biology with cancer and multiple myeloma research while clearly separating evidence from hypothesis.
-
Procainamide Hydrochloride: Assay Design Guide
2026-08-25
Procainamide Hydrochloride is a cardiac sodium channel blocker with applications spanning electrophysiology and combination oncology research. This guide translates its channel pharmacology, chemical properties, and liposomal cisplatin evidence into practical assay-design decisions.
-
Rapamycin (Sirolimus): mTOR Research Workflows
2026-08-25
Build reproducible mTOR perturbation experiments with Rapamycin (Sirolimus), from nanomolar dose finding to pathway-validated cell assays. This guide also shows how the reference study’s HIF-1 and ferroptosis workflow can inform, but not replace, direct validation of rapamycin biology.
-
7-dehydro Cholesterol: A Sterol–Immunity Assay Map
2026-08-24
Explore how 7-dehydro Cholesterol and DHCR7 biology connect cholesterol biosynthesis, vitamin D3 formation, and antiviral immunity. This guide translates an in vivo grass carp study into practical decisions for sterol, UVB, skin-model, and metabolic assays.
-
FMO3–TMAO Signalling in Aging Adipose Tissue
2026-08-24
This doctoral thesis identifies white adipose tissue as an important source of FMO3-derived trimethylamine N-oxide during aging, extending the conventional liver-centered model of TMAO biology. Its adipocyte-specific knockout and mechanistic analyses connect the FMO3–TMAO axis with p53-associated senescence, NLRP3 inflammasome activation, inflammation, fibrosis, and metabolic dysfunction.
-
CLCC1 and Herpesvirus Nuclear Egress
2026-08-23
A 2024 bioRxiv preprint identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of herpes simplex virus 1 nuclear egress. The study combines genome-wide CRISPR screening with cellular and virological analyses to connect CLCC1 loss with perinuclear vesicle accumulation, impaired nuclear pore insertion, and reduced viral production.
-
Phosphatase Inhibitor Cocktail 1: JAK–STAT3
2026-08-22
Phosphatase Inhibitor Cocktail 1 can preserve phosphorylation-dependent signals during pancreatic cancer sample preparation. This article explains how to match its alkaline and serine/threonine phosphatase coverage to JAK2–STAT3 assays without overinterpreting phosphosite data.
-
C34 TLR4 Inhibitor: Mechanism and Evidence
2026-08-22
C34 is a selective small-molecule TLR4 inhibitor for inflammatory signaling research, with reported activity in macrophage, enterocyte, animal endotoxemia, and necrotizing enterocolitis models. The product dossier reports an approximately 10 μM in vitro benchmark and an approximately 1 mg/kg in vivo benchmark under model-specific conditions.
-
Standardized Whole-Blood Immune Metabolism
2026-08-21
Zhao and colleagues present a standardized whole-blood stimulation protocol for testing how metabolic interventions reshape human immune responses. By combining defined immune stimuli, pathway-directed inhibitors, and cytokine measurements, the workflow reveals selective, stimulus-dependent effects that can support cohort studies and translational immunometabolism research.
-
Isoprinosine in Herpesvirus Egress Assays
2026-08-20
Use Isoprinosine as a controlled antiviral-immunomodulatory perturbation, not as a presumed direct CLCC1 inhibitor. This workflow combines infectious-titer, genome-copy, and imaging readouts to distinguish replication effects from herpesvirus nuclear-egress defects identified in a recent CRISPR study.